Financial Company Profile

Helicos BioSciences (NASDAQ: HLCS) is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets. Helicos’ proprietary True Single Molecule Sequencing, tSMS™, technology allows direct measurement of billions of strands of DNA enabling scientists to perform experiments and ask questions never before possible. Helicos is a recipient of the $1,000 genome grant and committed to providing scientists the tools to unlock the era of genomic medicine. The company is currently commercializing its first product, the Helicos™ Genetic Analysis System.

Based on Helicos’ tSMS technology, the Helicos Genetic Analysis System enables ultra high-throughput genetic analysis by directly sequencing single molecules of nucleic acids. The tSMS workflow is based on a simple, cost effective sample preparation process that can easily be scaled and replicated to meet the requirements of large, complex experiments, overcoming laboratory workflow bottlenecks.

Helicos believes the tSMS sequencing by synthesis approach represents the first comprehensive and universal solution for single molecule genetic analysis, dramatically lowering the cost of individual analyses. The Helicos Genetic Analysis System has extensive capabilities in basic and translational research, and pharmaceutical R&D, thus increasing the potential for improved drug therapies, personalized medicine and more accurate molecular diagnostics for diseases such as cancer.

The Helicos leadership team is comprised of eight experienced industry leaders with an extensive track record of leading successful life science companies within their respective disciplines. The team includes Steve Lombardi, President and Chief Executive Officer; Stephen Hall, Senior Vice President and Chief Financial Officer; Bill Efcavitch, PhD, Senior Vice President and Chief Technology Officer; Marc S. Levine, Senior Vice President of Product Development; Patrice M. Milos, PhD, VicePresident and Chief Scientific Officer; Chip Leveille, Vice President of Sales and Marketing; Alan Sherr, Vice President of Intellectual Property and Mark Solakian, Vice President and General Counsel.

In addition, Helicos has a preeminent group of scientists and technologists on its Scientific Advisory Board, including Dr. Leroy Hood, MD, PhD, President of the Institute for Systems Biology, and Steven Chu, PhD, Director of the Lawrence Berkeley National Laboratory and winner of the 1997 Nobel Prize for Physics. The company’s corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is 617-264-1800.

For more information, please visit www.helicosbio.com.